Hims & Hers Health, Inc. (HIMS)
Automate Your Wheel Strategy on HIMS
With Tiblio's Option Bot, you can configure your own wheel strategy including HIMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol HIMS
- Rev/Share 8.038
- Book/Share 2.4743
- PB 21.3275
- Debt/Equity 0.1154
- CurrentRatio 1.5942
- ROIC 0.2452
- MktCap 11369507580.0
- FreeCF/Share 1.0821
- PFCF 47.3302
- PE 71.2575
- Debt/Assets 0.0711
- DivYield 0
- ROE 0.3597
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | HIMS | Needham | -- | Buy | $61 | $65 | June 4, 2025 |
| Downgrade | HIMS | TD Cowen | Buy | Hold | -- | $30 | April 29, 2025 |
| Downgrade | HIMS | Morgan Stanley | Overweight | Equal Weight | $42 | $60 | Feb. 18, 2025 |
| Downgrade | HIMS | Citigroup | Neutral | Sell | $24 | $25 | Jan. 10, 2025 |
| Initiation | HIMS | BTIG Research | -- | Buy | -- | $35 | Jan. 7, 2025 |
| Initiation | HIMS | Morgan Stanley | -- | Overweight | -- | $42 | Dec. 17, 2024 |
| Initiation | HIMS | Needham | -- | Buy | -- | $24 | Aug. 22, 2024 |
News
HIMS' Buyouts Fuel International Expansion & Digital Health Innovation
Published: June 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers accelerates European growth with new ZAVA acquisition, adding localized care and lab testing innovation.
Read More
Hims & Hers Stock: Buy the Dip or Wait It Out?
Published: June 05, 2025 by: MarketBeat
Sentiment: Positive
One of the most exciting growth stories in the market is that of Hims & Hers Health Inc. NYSE: HIMS. This company has combined the growth and efficiency aspects of the technology sector with the safety and stability of the medical sector.
Read More
HIMS Stock Falls Despite Latest Deal to Expand International Footprint
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers is set to acquire ZAVA to launch in Germany, France and Ireland, deepening its personalized digital health push.
Read More
Why Is Hims & Hers Health (HIMS) Up 10.6% Since Last Earnings Report?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock?
Read More
Which Telehealth Stock Should You Be Targeting?
Published: June 03, 2025 by: Schaeffers Research
Sentiment: Positive
Hims & Hers Health Inc (NYSE:HIMS) stock made waves in premarket trading, after the telehealth firebrand announced the pending acquisition of ZAVA, a European digital health platform.
Read More
Top Stock Movers Now: Dollar General, Hims & Hers, Bumble, and More
Published: June 03, 2025 by: Investopedia
Sentiment: Positive
U.S. equities rose at midday as the markets continued to wait for more information about possible U.S. trade deals. The Dow Jones Industrial Average, S&P 500, and Nasdaq were slightly higher.
Read More
Hims & Hers Expands in Europe With Acquisition of ZAVA
Published: June 03, 2025 by: Investopedia
Sentiment: Positive
Hims & Hers Health (HIMS) shares rose Tuesday after the health and wellness site announced it was expanding its reach into Europe by buying London-based digital health platform ZAVA. The price of the all-cash deal was not disclosed.
Read More
Hims expands into Europe with Zava acquisition
Published: June 03, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Brandon Gomez reports on the latest news regarding Hims.
Read More
The Bull Market is Back: 3 Stocks to Buy Now (HIMS, APP, META)
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers Health, AppLovin and Meta Platforms all boast a litany of bullish catalysts driving their stock prices higher.
Read More
Why Hims & Hers Health, Inc. (HIMS) is a Top Momentum Stock for the Long-Term
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Hims & Hers expands into Europe with Zava acquisition
Published: June 03, 2025 by: Proactive Investors
Sentiment: Positive
Hims & Hers (NYSE:HIMS), a leading US-based health and wellness platform, is expanding into Europe via its acquisition of telehealth platform and online pharmacy Zava. The company said the acquisition will expand its footprint in the UK and launch the company in Germany, France and Ireland, with additional markets expected soon.
Read More
Hims & Hers stock rockets on news of European launch
Published: June 03, 2025 by: Finbold
Sentiment: Positive
Hims & Hers Health (NYSE: HIMS) experienced a notable uptick in its stock price following the announcement of its planned acquisition of ZAVA, a prominent European digital health platform.
Read More
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
Read More
Hims to acquire UK-based startup Zava as it expands international presence
Published: June 03, 2025 by: Reuters
Sentiment: Positive
Telehealth platform Hims & Hers said on Tuesday it will acquire London-based startup Zava for an undisclosed amount, allowing it to launch its offerings in Germany, France and Ireland and reach more international patients.
Read More
Hims & Hers to acquire European telehealth platform in global expansion
Published: June 03, 2025 by: CNBC
Sentiment: Positive
Hims & Hers Health announced Tuesday it will acquire European telehealth platform Zava. The deal will expand Hims' services to Ireland, France and Germany and will grow its active customer base by roughly 50%.
Read More
Hims & Hers: Still Huge Potential Ahead
Published: June 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Hims & Hers Health, Inc is a telehealth platform offering tailored health and wellness services, showing significant stock volatility recently. HIMS experienced a dramatic rise from $24.11 to $68.75 in February but has since settled at $49.47. Financials reveal a 111% YoY revenue increase to $586 million and a 77.5% rise in net income to $49.5 million.
Read More
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Read More
Hims to cut 4% of workforce amid ban on weight-loss drug copies
Published: May 30, 2025 by: Reuters
Sentiment: Negative
Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S. ban on manufacturing mass copies of the weight-loss drug Wegovy.
Read More
Hims & Hers vs. Amwell: Which Telehealth Stock Is the Better Buy?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
HIMS targets personalized, AI-powered care with bold obesity moves, while AMWL bets on system-wide integration via Converge and top-tier health alliances. Who wins? Let's see.
Read More
Hims & Hers Health Stock: After Doubling, It May Be Too Late To Buy
Published: May 29, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health shows strong growth in subscribers, revenue, and profitability, driven by expanding offerings and strategic partnerships, especially in weight loss and dermatology. HIMS posted stellar Q1 FY 2025: Revenue +110%, EBITDA +181%, EPS +300%. Growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Management's ambitious 2030 strategy leverages AI, new specialties, and global expansion, aiming for significant top-line and EPS growth.
Read More
Hims & Hers Stock Falls Despite the Latest Wegovy Availability Offer
Published: May 28, 2025 by: Zacks Investment Research
Sentiment: Neutral
HIMS launches six-month Wegovy access at $549/month, aiming to expand affordable obesity care with holistic weight loss solutions.
Read More
Cautious? Risky? Our Volatility Scorecard Can Help
Published: May 27, 2025 by: Schaeffers Research
Sentiment: Neutral
Our volatility scorecard has a pretty good feel for the market right now.
Read More
Avoid These Dividend Disasters Before It's Too Late
Published: May 23, 2025 by: Seeking Alpha
Sentiment: Negative
Dividend stocks are facing many big risks. The high interest rates, trade war, and AI revolution could lead to many dividend cuts. I discuss what this all means for dividend investors.
Read More
Hims & Hers Introduces 6-Month Wegovy® New Customer Offer
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans. “We are always looking for long-term, sustainable ways to increase access to care for our customers,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “This is another example of how.
Read More
Will Hims & Hers Stock Be Okay After UnitedHealth's Sell-Off?
Published: May 22, 2025 by: MarketBeat
Sentiment: Neutral
When investors choose to risk their capital in an individual company, they must be aware that the stock market isn't the one-sided machine it used to be a few decades ago. Thanks to the flow of information and availability in the digital space, today's market has become more interconnected than ever before.
Read More
5 Single-Stock ETFs That Doubled in a Month
Published: May 21, 2025 by: Zacks Investment Research
Sentiment: Positive
We have highlighted five single-stock ETFs that have doubled over the past month amid a historic Wall Street comeback.
Read More
Hims & Hers: After A Bout Of Uncertainty, Upside Remains
Published: May 21, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers continues to deliver strong subscriber and revenue growth, with Q1 2025 revenue up 111% year-over-year and operating leverage improving. The business model's shift to a subscription platform with personalized care unlocks significant long-term free cash flow and expansion opportunities. Management's guidance and execution support a path to $6.5B in revenue by 2030, with my valuation thesis still intact and suggesting undervaluation.
Read More
Hims & Hers Stock Chart Points to Strong Bullish Continuation
Published: May 20, 2025 by: MarketBeat
Sentiment: Positive
Hims and Hers, Inc. NYSE: HIMS shows strongly bullish signs that begin and end with the stock price action. It reflects volatility, but the bias is upward with rising support and the most recent swing, a bullish rebound, looks very strong within the pattern.
Read More
Here's Why You Should Add Hims & Hers Stock to Your Portfolio Now
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Hims & Hers leads with AI-powered, personalized health plans (over 70% of new users opt in). Recurring revenues surge as tailored care drives loyalty.
Read More
Hims & Hers Stock Declines 3.1% in 3 Months: Is it a Buy Now?
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Negative
HIMS is expanding its health and wellness products and services and increasing its focus on AI to solidify its footing. However, macro challenges may hurt performance.
Read More
About Hims & Hers Health, Inc. (HIMS)
- IPO Date 2019-09-13
- Website https://www.forhims.com
- Industry Household & Personal Products
- CEO Mr. Andrew Dudum
- Employees 1637